Companies › Shanghai Henlius Biotech
20 active drug programs in 146 registered trials: 105 Phase 2, 21 Phase 1, 18 Phase 3, 2 Phase 4; Oncology, Genitourinary, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Serplulimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Extensive Stage Small Cell Lung Cancer; Limited-Stage Small Cell Lung Cancer; Non Small Cell Lung Cancer; Metastatic Colorectal Cancer … | Nov 2026 |
| HLX22 HER2-targeted monoclonal antibody | ERBB2 | Phase 3 | Gastroesophageal-junction Cancer; HER2-low Hormone Receptor Positive Breast Cancer; HER2 + Breast Cancer | Jun 2027 |
| Pertuzumab (HLX11) Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Breast Cancer; Elderly Females; Metastatic Breast Cancer; Invasive Breast Cancer … | – |
| HLX43 anti-PD-L1 antibody-drug conjugate with topoisomerase I inhibitor payload | CD274 | Phase 2 | Nasopharyngeal Carcinoma (NPC); Non Small Cell Lung Cancer; Colorectal Cancer (CRC); Cervical Cancer … | Nov 2026 |
| Bevacizumab (HLX04) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 2 | Metastatic Colorectal Cancer; Carcinoma, Hepatocellular | Dec 2026 |
| HLX79 Human sialidase fusion protein | – | Phase 2 | Membranous Nephropathy | Jan 2027 |
| Rituximab (HLX01) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 2 | Membranous Nephropathy | Jan 2027 |
| HLX53 Anti-TIGIT Fc fusion protein | TIGIT | Phase 2 | Carcinoma, Hepatocellular | Feb 2027 |
| HLX26 Anti-LAG-3 monoclonal antibody | LAG3 | Phase 2 | NSCLC Stage IV | Jul 2027 |
| Pimurutamab (HLX07) Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 2 | Carcinoma of Head and/or Neck; Advanced or Metastatic Squamous Non-Small Cell Lung Cancer; Rectal Cancer | Dec 2027 |
| HLX13 CTLA-4 inhibitor (anti-CTLA-4 monoclonal antibody biosimilar) | CTLA4 | Phase 1 | Hepatocellular Carcinoma (HCC) | Dec 2026 |
| HLX05 anti-EGFR monoclonal antibody | EGFR | Phase 1 | Cancer; EGFR Overexpression | Dec 2026 |
| HLX48 EGFR/c-MET bispecific antibody-drug conjugate | EGFR, MET | Phase 1 | Advanced/Metastatic Solid Tumors | Mar 2027 |
| Pembrolizumab (HLX17) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 1 | Non-small Cell Lung Cancer | Apr 2027 |
| HLX15-SC anti-CD38 monoclonal antibody | SDCL2 | Phase 1 | Multiple Myeloma (MM) | May 2027 |
| Cetuximab (HLX42) Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 1 | Solid Tumor and NSCLC | Jun 2027 |
| HLX3902 | – | Phase 1 | mCRPC or Advanced/Metastatic Solid Tumors | Jun 2027 |
| HLX18 PD-1 inhibitor | PDCD1 | Phase 1 | Esophageal and/or Cardia Cancer | Aug 2027 |
| HLX316 | – | Phase 1 | Advanced/Metastatic Solid Tumors | Dec 2027 |
| HLX3901 | – | Phase 1 | SCLC | May 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03161353 | Pertuzumab (HLX11) | Phase 2 | Breast Cancer | Oncology | Nov 2023 |
| NCT05346224 | Pertuzumab (HLX11) | Phase 3 | Breast Cancer | Oncology | May 2024 |
| NCT02625441 | Pertuzumab (HLX11) | Phase 3 | Breast Cancer | Oncology | Jun 2025 |
| NCT04680442 | Pertuzumab (HLX11) | Phase 2 | Breast Cancer | Oncology | Dec 2025 |
| NCT06980454 | HLX05 | Phase 1 | Cancer | Oncology | Dec 2025 |
| NCT06368141 | Serplulimab | Phase 2 | Colon Cancer | Oncology | Feb 2026 |
| NCT05585580 | Serplulimab | Phase 2 | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Apr 2026 |
| NCT06911606 | Serplulimab | Phase 2 | SCLC, Limited Stage | Oncology | Jun 2026 |
| NCT06576921 | Serplulimab | Phase 2 | Stomach Neoplasms | Oncology | Aug 2026 |
| NCT06839066 | HLX43 | Phase 2 | Nasopharyngeal Carcinoma (NPC) | Oncology | Nov 2026 |
| NCT07269782 | HLX43 | Phase 2 | Non Small Cell Lung Cancer | Oncology | Nov 2026 |
| NCT07269782 | Serplulimab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Nov 2026 |
| NCT07108127 | Pertuzumab (HLX11) | Phase 2 | Rectal Cancer | Oncology | Dec 2026 |
| NCT03595592 | Pertuzumab (HLX11) | Phase 3 | Invasive Breast Cancer | Oncology | Dec 2026 |
| NCT05891561 | Pertuzumab (HLX11) | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT06542588 | Serplulimab | Phase 2 | Rectal Cancer | Oncology | Dec 2026 |
| NCT07283692 | Serplulimab | Phase 2 | Triple Negative Breast Cancer | Oncology | Dec 2026 |
| NCT06497530 | Serplulimab | Phase 2 | Extensive-Stage Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06542588 | Pimurutamab (HLX07) | Phase 2 | Rectal Cancer | Oncology | Dec 2026 |
| NCT07176650 | HLX13 | Phase 1 | Hepatocellular Carcinoma (HCC) | Oncology | Dec 2026 |
| NCT05954429 | Serplulimab | Phase 2 | Colorectal Cancer | Oncology | Dec 2026 |
| NCT07106892 | HLX43 | Phase 2 | Colorectal Cancer (CRC) | Oncology | Dec 2026 |
| NCT04547166 | Serplulimab | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2026 |
| NCT05837052 | Serplulimab | Phase 2 | Unresectable Lung Non-Small Cell Carcinoma | Oncology | Dec 2026 |
| NCT05731726 | Serplulimab | Phase 2 | pMMR | Oncology | Dec 2026 |
| NCT04547166 | Bevacizumab (HLX04) | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2026 |
| NCT06769152 | HLX43 | Phase 2 | Cervical Cancer | Oncology | Dec 2026 |
| NCT04750122 | Pertuzumab (HLX11) | Phase 1 | HER2-positive Early Breast Cancer | Oncology | Dec 2026 |
| NCT06727617 | Serplulimab | Phase 2 | Cervical Cancers | Oncology | Dec 2026 |
| NCT05765825 | Serplulimab | Phase 2 | Extensive-stage Small-cell Lung Cancer | Oncology | Dec 2026 |
| NCT06280495 | Serplulimab | Phase 2 | Colorectal Cancer | Oncology | Dec 2026 |
| NCT06433869 | Serplulimab | Phase 2 | Malignant Ascites | Oncology | Dec 2026 |
| NCT05957510 | Serplulimab | Phase 2 | Small-cell Lung Cancer | Oncology | Dec 2026 |
| NCT06309043 | HLX05 | Phase 1 | EGFR Overexpression | Other | Dec 2026 |
| NCT06136897 | Pertuzumab (HLX11) | Phase 2 | Malignant Solid Neoplasm | Oncology | Jan 2027 |
| NCT07038382 | HLX79 | Phase 2 | Membranous Nephropathy | Genitourinary | Jan 2027 |
| NCT07038382 | Rituximab (HLX01) | Phase 2 | Membranous Nephropathy | Genitourinary | Jan 2027 |
| NCT06295926 | Serplulimab | Phase 2 | Small Cell Lung Cancer | Oncology | Jan 2027 |
| NCT07257575 | Serplulimab | Phase 2 | Gastric Cancer Stage III | Oncology | Jan 2027 |
| NCT06349980 | Serplulimab | Phase 2 | Carcinoma, Hepatocellular | Oncology | Feb 2027 |
| NCT06349980 | Bevacizumab (HLX04) | Phase 2 | Carcinoma, Hepatocellular | Oncology | Feb 2027 |
| NCT06349980 | HLX53 | Phase 2 | Carcinoma, Hepatocellular | Oncology | Feb 2027 |
| NCT07277439 | Serplulimab | Phase 2 | Gastric Cancer | Oncology | Feb 2027 |
| NCT07473726 | HLX48 | Phase 1 | Advanced/Metastatic Solid Tumors | Oncology | Mar 2027 |
| NCT06601309 | Serplulimab | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Mar 2027 |
| NCT05766800 | Serplulimab | Phase 2 | Locally Advanced | Oncology | Apr 2027 |
| NCT04588545 | Pertuzumab (HLX11) | Phase 1 | HER2-positive Breast Cancer | Oncology | Apr 2027 |
| NCT07101679 | Serplulimab | Phase 2 | Locally Advanced Pancreatic Ductal Adenocarcinoma | Oncology | Apr 2027 |
| NCT07160335 | Pembrolizumab (HLX17) | Phase 1 | Non-small Cell Lung Cancer | Oncology | Apr 2027 |
| NCT07583511 | Serplulimab | Phase 2 | Small-cell Lung Cancer | Oncology | May 2027 |
| NCT07477587 | HLX15-SC | Phase 1 | Multiple Myeloma (MM) | Oncology | May 2027 |
| NCT07596121 | Serplulimab | Phase 2 | NSCLC (Non-small Cell Lung Cancer) | Oncology | May 2027 |
| NCT06532006 | HLX22 | Phase 3 | Gastroesophageal-junction Cancer | Oncology | Jun 2027 |
| NCT06832202 | HLX22 | Phase 2 | HER2-low Hormone Receptor Positive Breast Cancer | Oncology | Jun 2027 |
| NCT06742892 | HLX43 | Phase 2 | Carcinoma, Hepatocellular | Oncology | Jun 2027 |
| NCT06769113 | HLX43 | Phase 2 | Esophageal Cancer | Oncology | Jun 2027 |
| NCT06210815 | Cetuximab (HLX42) | Phase 1 | Solid Tumor and NSCLC | Oncology | Jun 2027 |
| NCT07253142 | Serplulimab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT07253142 | Serplulimab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT07533708 | HLX3902 | Phase 1 | mCRPC or Advanced/Metastatic Solid Tumors | Oncology | Jun 2027 |
The 60 nearest readouts of 146 trials; the rest in the app.
Sichuan Baili Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shenyang Sunshine Pharmaceutical Akeso Merck KGaA
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.